ASMTL

Across TCGA pan-cancer cohorts, ASMTL mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ASMTL data layer compared with 25 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ASMTL mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ASMTL expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LUAD show a favorable association.

CCRCC, LUAD, and HNSC are the cancer types where ASMTL mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	III,IV	0.739	0.394	.003	43	view →
LUAD	DFS	Median	All	0.978	0.617	.002	17	view →
HNSC	OS	Median	All	1.000	0.484	.038	13	view →
COAD	DFS	Median	III,IV	1.000	0.838	.036	6	view →
PDAC	OS	Median	IV	0.836	0.491	.024	3	view →
LSCC	DFS	Median	III,IV	0.882	1.000	.039	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ASMTL–CCRCC (DFS)

Open the CCRCC breakdown →